Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2011 by Sheba Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT01272310
First received: January 3, 2011
Last updated: January 6, 2011
Last verified: January 2011
  Purpose

The study is aimed to investigate the safety, tolerability and efficacy of a fixed dose combination therapy of: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (PEG-IFN alpha-2a) and Ribavirin (RBV) in Chronic Hepatitis C Genotype 1 Infected adult subjects who failed to respond following a course of PEG-IFN and RBV Therapy.


Condition Intervention Phase
Chronic Hepatitis C
Biological: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II, Open Clinical Trial to Assess the Safety, Tolerability and Efficacy of a Fixed Dose Combination Therapy of: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN Alpha-2a) and Ribavirin (RBV) in Chronic Hepatitis C Genotype 1 Infected Subjects Who Failed to Respond Following a Course of Peg-IFN and RBV Therapy (SoC).

Resource links provided by NLM:


Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:
  • Change from baseline in physical examination [ Time Frame: Twice on study first week , once a week during treatment initiation at weeks 2,3 ,4, later during treatment period once a month at weeks 8-48 and at weeks 60 and 72 follow up visits post treatment ] [ Designated as safety issue: Yes ]
    Body system screaning

  • Change from baseline in vital Signs [ Time Frame: Twice on study first week , once a week during treatment initiation at weeks 2,3 ,4, later during treatment period once a month at weeks 8-48 and at weeks 60 and 72 follow up visits post treatment ] [ Designated as safety issue: No ]
    Heart Rate, Blood Presure, Respiratory Rate , Body temperature

  • Change from baseline in clinical laboratory parameters [ Time Frame: Twice on study first week , once a week during treatment initiation at weeks 2,3 ,4, later during treatment period once a month at weeks 8-48 and at weeks 60 and 72 follow up visits post treatment ] [ Designated as safety issue: Yes ]
    Hematology, Blood Chemistry, Coagulation parameters, Urinalysis

  • Change from baseline in adverse events [ Time Frame: Twice on study first week , once a week during treatment initiation at weeks 2,3 ,4, later during treatment period once a month at weeks 8-48 and at weeks 60 and 72 follow up visits post treatment ] [ Designated as safety issue: Yes ]
    All observed and or reported adverse events


Secondary Outcome Measures:
  • HCV RNA level [ Time Frame: at 4,12, 24, 48 and 72 weeks after treatment ] [ Designated as safety issue: No ]
    Changes in HCV RNA levels, monitored along the study period. The efficacy of a HCQ-containing treatment regimen defined as the proportion of subjects with SVR i.e. undetectable HCV RNA <50 IU/ml) at 5 different time points: cEVR at 12 weeks, 4 weeks, 24 weeks, 48 weeks after treatment initiation and at 24 weeks after end of treatment (week 72).


Estimated Enrollment: 36
Study Start Date: January 2011
Estimated Study Completion Date: July 2013
Estimated Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Combination therapy Biological: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin

HCQ will be taken daily as an oral tablet of 200 mg b.i.d. Pegylated Interferon Alpha-2a - (180 µg) will be administered as weekly subcutaneous (s.c.) injections of 0.5 ml.

Ribavirin - will be taken daily based on the patient body weight. If body weight is < 75 kg, the total daily dose of Copegus® is 1000 mg, administered as 400 mg (2 tablets of 200 mg, morning intake) and 600 mg (3 tablets of 200 mg, evening intake). If body weight is >= 75 kg, the total daily dose is 1200 mg administered as twice 600 mg (3 tablets of 200 mg per intake, morning and evening).

Other Names:
  • Copegus
  • Pegasys

Detailed Description:

This is a phase I/II, open clinical trial to assess the safety, tolerability and preliminary efficacy data of a fixed dose combination therapy of: HCQ, Peg-IFN alpha-2a and RBV in chronic hepatitis C genotype 1 infected subjects who failed to respond following a course of Peg-IFN and RBV Therapy (SoC). The study is a single center trial to be conducted at the Department of Gastroenterology & Hepatology, at Sheba Medical Center, Tel Hashomer, Israel.

Overall, thirty six (36) patients will be recruited. All patients enrolled will have a documented history of chronic HCV disease and being non-responder on earlier Peg-IFN based treatment lasting for at least 12 consecutive weeks prior to study enrolment.

The expected duration of patient screening period prior to enrollment into this study is in-between six weeks (42 days) up to 2 days prior to the study enrollment day at visit 2 (verification of compliance with inclusion/exclusion criteria including clinical laboratory results). Eligible patients will be enrolled into the study and will be observed twice on the first week of the study, once a week during the initiation of the treatment period at weeks 2,3 and week 4, later during the treatment period once a month at weeks 8-48 and at two follow up visits post treatment to take place at week 60 and 72 (allowing a time window of ± 5 days for all visits).

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and females between 18 and 70 years old.
  2. Subjects diagnosed to have positive HCV antibodies using a third generation test.
  3. Subject is diagnosed to have detectable HCV RNA by PCR.
  4. Liver biopsy or FibroTest showing a METAVIR score ≥F2 and/or ≥A2.
  5. Subject diagnosed to have compensated liver disease.
  6. Subject is non-responder (null or partial) on prior Peg-IFN and RBV based treatment lasting for at least 12 consecutive weeks.
  7. Treatment not discontinued due to intolerability to Peg-IFN or RBV.
  8. Subjects able to comprehend and give informed consent for participation in this study.
  9. Subject is willing to be treated and commit to all visits.

Exclusion Criteria:

  1. Anti HCV therapy contraindications.
  2. Subject is identified as a relapser on prior Peg-IFN and RBV based treatment.
  3. Hypersensitivity to one of the three drugs (HCQ, Peg-IFN, RBV).
  4. Patient has Anaemia,neutropenia, thrombocytopenia, elevated bilirubin levels, elevated ALT and/or AST, or elevated creatinin and INR greater than 1.5.
  5. Concomitant liver disease other than hepatitis C: chronic hepatitis B, alcoholic liver disease, autoimmune hepatitis, Wilson's disease, hemochromatosis, alpha-1 antitrypsin deficiency.
  6. Decompensated cirrhosis (Child Pugh >A).
  7. Clinical evidence for hepatocellular carcinoma.
  8. Human immunodeficiency virus co-infection.
  9. Major uncontrolled psychiatric illness. Minor or situational depressions are allowed.
  10. Active elicit drug or alcohol abuse.
  11. Serious co-morbid conditions as: heart failure, significant coronary heart disease, chronic obstructive pulmonary disease, renal insufficiency, poorly controlled diabetes, autoimmune disorders, and malignant diseases in the previous 5 years.
  12. Immunosuppressive treatment including corticosteroids,
  13. Untreated or uncontrolled or thyroid disease.
  14. Solid transplant organ (renal, heart, or lung).
  15. Pregnancy or unwillingness to practice double contraception or abstinence by the subject of childbearing potential or partner.
  16. Subject objects to the study protocol.
  17. Concurrent participation in any other clinical study within 30 days prior to enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01272310

Contacts
Contact: Yaakov Maor, Dr 97235302906 yaakov.maor@sheba.health.gov.il

Sponsors and Collaborators
Sheba Medical Center
  More Information

No publications provided

Responsible Party: Dr. Yaakov Maor, Sheba Medical Center
ClinicalTrials.gov Identifier: NCT01272310     History of Changes
Other Study ID Numbers: SHEBA-10-8033-YM-CTIL, HCQ-001-IL
Study First Received: January 3, 2011
Last Updated: January 6, 2011
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Sheba Medical Center:
Chronic Hepatitis C
Combination Therapy
Hydroxychloroquine
Pegylated Interferon Alpha-2a
Ribavirin
Chronic Hepatitis C Genotype 1 infected adult subjects

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Hydroxychloroquine
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin
Anti-Infective Agents
Antimalarials
Antimetabolites
Antineoplastic Agents
Antiparasitic Agents
Antiprotozoal Agents
Antirheumatic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 25, 2014